Comments
Loading...

Insmed Analyst Ratings

INSMNASDAQ
Logo brought to you by Benzinga Data
$65.61
-0.1-0.15%
At close: -
$65.61
0.000.00%
After Hours: 4:00 PM EDT
Q1 2025 Earnings were released on Thu May 8th, before the market open
The most recent conference call was at 8:00 AM, 6 days ago Click to view past webcast
Consensus Rating1
Buy
Highest Price Target1
$109.00
Lowest Price Target1
$42.00
Consensus Price Target1
$85.25

Insmed Analyst Ratings and Price Targets | NASDAQ:INSM | Benzinga

Insmed Corp has a consensus price target of $567.61 based on the ratings of 38 analysts. The high is $1350 issued by HSBC on May 10, 2024<. The low is $100 issued by Deutsche Bank on August 5, 2024. The 3 most-recent analyst ratings were released by New Street Research, Goldman Sachs, and Deutsche Bank on August 6, 2024, August 5, 2024, and August 5, 2024, respectively. With an average price target of $118.33 between New Street Research, Goldman Sachs, and Deutsche Bank, there's an implied 0.21% upside for Insmed Corp from these most-recent analyst ratings.

Analyst Trends and Forecast
1
Nov 24
13
Feb
3
Mar
1
Apr
2
May
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
4.3
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

Jefferies
UBS
HC Wainwright & Co.
B of A Securities
RBC Capital

1calculated from analyst ratings

Analyst Ratings for Insmed

Buy NowGet Alert
05/13/2025Buy NowJefferies
Kelly Shi39%
→ $105Initiates → BuyGet Alert
05/09/2025Buy NowUBS
Trung Huynh64%
$110 → $109MaintainsBuyGet Alert
04/22/2025Buy NowHC Wainwright & Co.
Andrew Fein55%
$90 → $90ReiteratesBuy → BuyGet Alert
03/20/2025Buy NowB of A Securities
Jason Zemansky69%
$92 → $96MaintainsBuyGet Alert
03/19/2025Buy NowRBC Capital
Leonid Timashev38%
$100 → $100ReiteratesOutperform → OutperformGet Alert
03/06/2025Buy NowUBS
Trung Huynh64%
$105 → $110MaintainsBuyGet Alert
02/25/2025Buy NowRBC Capital
Leonid Timashev38%
→ $100Initiates → OutperformGet Alert
02/25/2025Buy NowGuggenheim
Vamil Divan74%
$101 → $101ReiteratesBuy → BuyGet Alert
02/24/2025Buy NowHC Wainwright & Co.
Andrew Fein55%
$90 → $90ReiteratesBuy → BuyGet Alert
02/21/2025Buy NowTruist Securities
Nicole Germino42%
$105 → $108MaintainsBuyGet Alert
02/21/2025Buy NowStifel
Stephen Willey49%
$97 → $96MaintainsBuyGet Alert
02/21/2025Buy NowHC Wainwright & Co.
Andrew Fein55%
$90 → $90ReiteratesBuy → BuyGet Alert
02/20/2025Buy NowCantor Fitzgerald
Jennifer Kim44%
ReiteratesOverweight → OverweightGet Alert
02/19/2025Buy NowCantor Fitzgerald
Jennifer Kim44%
ReiteratesOverweight → OverweightGet Alert
02/19/2025Buy NowWells Fargo
Tiago Fauth42%
$85 → $107MaintainsOverweightGet Alert
02/11/2025Buy NowStifel
Stephen Willey49%
$88 → $97MaintainsBuyGet Alert
02/07/2025Buy NowJP Morgan
Jessica Fye65%
$83 → $92MaintainsOverweightGet Alert
02/07/2025Buy NowGuggenheim
Vamil Divan74%
$95 → $101MaintainsBuyGet Alert
02/06/2025Buy NowMorgan Stanley
Matthew Harrison60%
$85 → $90MaintainsOverweightGet Alert
11/22/2024Buy NowJP Morgan
Jessica Fye65%
$74 → $83MaintainsOverweightGet Alert
11/01/2024Buy NowTruist Securities
Nicole Germino42%
$100 → $105ReiteratesBuy → BuyGet Alert
11/01/2024Buy NowHC Wainwright & Co.
Andrew Fein55%
$90 → $90ReiteratesBuy → BuyGet Alert
10/11/2024Buy NowTruist Securities
Nicole Germino42%
$85 → $100MaintainsBuyGet Alert
10/09/2024Buy NowB of A Securities
Jason Zemansky69%
$84 → $86MaintainsBuyGet Alert
10/03/2024Buy NowJP Morgan
Jessica Fye65%
$72 → $74MaintainsOverweightGet Alert
09/09/2024Buy NowCantor Fitzgerald
Josh Schimmer51%
Reiterates → OverweightGet Alert
08/29/2024Buy NowHC Wainwright & Co.
Andrew Fein55%
$90 → $90ReiteratesBuy → BuyGet Alert
08/12/2024Buy NowTruist Securities
Nicole Germino42%
$88 → $85MaintainsBuyGet Alert
08/12/2024Buy NowHC Wainwright & Co.
Andrew Fein55%
$90 → $90ReiteratesBuy → BuyGet Alert
08/09/2024Buy NowTD Cowen
Ritu Baral24%
$75 → $98MaintainsBuyGet Alert
08/09/2024Buy NowUBS
Trung Huynh64%
$78 → $84MaintainsBuyGet Alert
08/09/2024Buy NowStifel
Stephen Willey49%
$74 → $88MaintainsBuyGet Alert
07/12/2024Buy NowMorgan Stanley
Matthew Harrison60%
$60 → $85MaintainsOverweightGet Alert
07/10/2024Buy NowGoldman Sachs
Andrea Tan37%
$74 → $102MaintainsBuyGet Alert
07/09/2024Buy NowGuggenheim
Vamil Divan74%
$70 → $95MaintainsBuyGet Alert
07/08/2024Buy NowHC Wainwright & Co.
Andrew Fein55%
$70 → $90MaintainsBuyGet Alert
07/05/2024Buy NowB of A Securities
Jason Zemansky69%
$83 → $83MaintainsBuyGet Alert
07/02/2024Buy NowHC Wainwright & Co.
Andrew Fein55%
$70 → $70ReiteratesBuy → BuyGet Alert
07/01/2024Buy NowTruist Securities
Nicole Germino42%
$68 → $88MaintainsBuyGet Alert
06/28/2024Buy NowB of A Securities
Jason Zemansky69%
$62 → $83MaintainsBuyGet Alert
06/21/2024Buy NowEvercore ISI Group
Josh Schimmer51%
$42 → $75MaintainsOutperformGet Alert
06/20/2024Buy NowCantor Fitzgerald
Jennifer Kim44%
Reiterates → OverweightGet Alert
06/20/2024Buy NowJP Morgan
Jessica Fye65%
$55 → $72MaintainsOverweightGet Alert
06/07/2024Buy NowMizuho
Graig Suvannavejh51%
$36 → $82MaintainsBuyGet Alert
06/05/2024Buy NowStifel
Stephen Willey49%
$67 → $74MaintainsBuyGet Alert
05/31/2024Buy NowStifel
Stephen Willey49%
$39 → $67MaintainsBuyGet Alert
05/29/2024Buy NowTD Cowen
Ritu Baral24%
$45 → $67MaintainsBuyGet Alert
05/29/2024Buy NowUBS
Trung Huynh64%
$46 → $58MaintainsBuyGet Alert
05/29/2024Buy NowGoldman Sachs
Andrea Tan37%
$49 → $74MaintainsBuyGet Alert
05/29/2024Buy NowWells Fargo
Tiago Fauth42%
$55 → $77MaintainsOverweightGet Alert
05/29/2024Buy NowTruist Securities
Nicole Germino42%
$48 → $68MaintainsBuyGet Alert
05/29/2024Buy NowBarclays
Leon Wang64%
$40 → $63MaintainsOverweightGet Alert
05/29/2024Buy NowJP Morgan
Jessica Fye65%
$36 → $55MaintainsOverweightGet Alert
05/29/2024Buy NowB of A Securities
Jason Zemansky69%
$40 → $62MaintainsBuyGet Alert
05/29/2024Buy NowHC Wainwright & Co.
Andrew Fein55%
$52 → $70MaintainsBuyGet Alert
05/28/2024Buy NowMorgan Stanley
Matthew Harrison60%
$43 → $60MaintainsOverweightGet Alert
05/28/2024Buy NowB of A Securities
Jason Zemansky69%
$40 → $40MaintainsBuyGet Alert
05/16/2024Buy NowTruist Securities
Nicole Germino42%
$48 → $48MaintainsBuyGet Alert
05/15/2024Buy NowGoldman Sachs
Andrea Tan37%
$40 → $49MaintainsBuyGet Alert
05/14/2024Buy NowHC Wainwright & Co.
Andrew Fein55%
$52 → $52ReiteratesBuy → BuyGet Alert
05/13/2024Buy NowMizuho
Graig Suvannavejh51%
$35 → $36MaintainsBuyGet Alert
05/10/2024Buy NowMorgan Stanley
Matthew Harrison60%
$40 → $43MaintainsOverweightGet Alert
04/23/2024Buy NowTruist Securities
Nicole Germino42%
→ $48Initiates → BuyGet Alert
04/11/2024Buy NowBarclays
Leon Wang64%
$37 → $40MaintainsOverweightGet Alert
04/01/2024Buy NowWells Fargo
Tiago Fauth42%
$55 → $55MaintainsOverweightGet Alert
02/27/2024Buy NowGuggenheim
Vamil Divan74%
$52 → $54MaintainsBuyGet Alert
02/27/2024Buy NowUBS
Trung Huynh64%
→ $46Initiates → BuyGet Alert
02/23/2024Buy NowB of A Securities
Jason Zemansky69%
$37 → $40MaintainsBuyGet Alert
02/15/2024Buy NowWolfe Research
Andy Chen39%
→ $42Initiates → OutperformGet Alert
11/20/2023Buy NowJP Morgan
Jessica Fye65%
→ $36Reinstates → OverweightGet Alert
10/27/2023Buy NowMizuho
Graig Suvannavejh51%
$33 → $35MaintainsBuyGet Alert
09/21/2023Buy NowCantor Fitzgerald
Jennifer Kim44%
$46 → $54MaintainsOverweightGet Alert
09/19/2023Buy NowCantor Fitzgerald
Jennifer Kim44%
→ $46ReiteratesOverweight → OverweightGet Alert
09/07/2023Buy NowEvercore ISI Group
Josh Schimmer51%
$32 → $42MaintainsOutperformGet Alert
09/06/2023Buy NowMizuho
Graig Suvannavejh51%
$30 → $33MaintainsBuyGet Alert
09/06/2023Buy NowB of A Securities
Jason Zemansky69%
$35 → $37MaintainsBuyGet Alert
09/06/2023Buy NowHC Wainwright & Co.
Andrew Fein55%
→ $52ReiteratesBuy → BuyGet Alert
09/05/2023Buy NowGuggenheim
Vamil Divan74%
$50 → $52ReiteratesBuy → BuyGet Alert
08/04/2023Buy NowStifel
Stephen Willey49%
$33 → $35MaintainsBuyGet Alert
08/04/2023Buy NowMorgan Stanley
Matthew Harrison60%
$41 → $41ReiteratesOverweight → OverweightGet Alert
08/04/2023Buy NowHC Wainwright & Co.
Andrew Fein55%
→ $52ReiteratesBuy → BuyGet Alert
07/26/2023Buy NowMizuho
Graig Suvannavejh51%
$28 → $30MaintainsBuyGet Alert
07/26/2023Buy NowGuggenheim
Vamil Divan74%
→ $50Initiates → BuyGet Alert
05/09/2023Buy NowHC Wainwright & Co.
Andrew Fein55%
→ $52Reiterates → BuyGet Alert
02/24/2023Buy NowCantor Fitzgerald
Jennifer Kim44%
$49 → $46MaintainsOverweightGet Alert
02/24/2023Buy NowCredit Suisse
Judah Frommer65%
→ $46Reiterates → OutperformGet Alert
02/24/2023Buy NowHC Wainwright & Co.
Andrew Fein55%
→ $52Reiterates → BuyGet Alert
01/20/2023Buy NowBarclays
Leon Wang64%
$37 → $35MaintainsOverweightGet Alert
01/09/2023Buy NowGoldman Sachs
Andrea Tan37%
$44 → $39MaintainsBuyGet Alert
12/09/2022Buy NowMizuho
Graig Suvannavejh51%
→ $28Initiates → BuyGet Alert
12/08/2022Buy NowBarclays
Leon Wang64%
→ $37Initiates → OverweightGet Alert
12/07/2022Buy NowBarclays
Leon Wang64%
→ $37Initiates → OverweightGet Alert
11/18/2022Buy NowB of A Securities
Jason Zemansky69%
→ $39Initiates → BuyGet Alert
10/27/2022Buy NowSVB Leerink
Joseph Schwartz64%
$52 → $50MaintainsOutperformGet Alert
10/25/2022Buy NowCantor Fitzgerald
Jennifer Kim44%
$53 → $49MaintainsOverweightGet Alert
10/21/2022Buy NowCowen & Co.
Ritu Baral24%
$56 → $53MaintainsOutperformGet Alert
07/15/2022Buy NowMorgan Stanley
Matthew Harrison60%
$46 → $41MaintainsOverweightGet Alert
05/24/2022Buy NowGoldman Sachs
Andrea Tan37%
$56 → $48MaintainsBuyGet Alert

FAQ

Q

What is the target price for Insmed (INSM) stock?

A

The latest price target for Insmed (NASDAQ:INSM) was reported by Jefferies on May 13, 2025. The analyst firm set a price target for $105.00 expecting INSM to rise to within 12 months (a possible 60.04% upside). 59 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Insmed (INSM)?

A

The latest analyst rating for Insmed (NASDAQ:INSM) was provided by Jefferies, and Insmed initiated their buy rating.

Q

When was the last upgrade for Insmed (INSM)?

A

There is no last upgrade for Insmed

Q

When was the last downgrade for Insmed (INSM)?

A

There is no last downgrade for Insmed.

Q

When is the next analyst rating going to be posted or updated for Insmed (INSM)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Insmed, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Insmed was filed on May 13, 2025 so you should expect the next rating to be made available sometime around May 13, 2026.

Q

Is the Analyst Rating Insmed (INSM) correct?

A

While ratings are subjective and will change, the latest Insmed (INSM) rating was a initiated with a price target of $0.00 to $105.00. The current price Insmed (INSM) is trading at is $65.61, which is within the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch